High survivorship and excellent functional outcome in third-generation patellofemoral arthroplasty

第三代髌股关节置换术具有较高的生存率和优异的功能结果

阅读:1

Abstract

PURPOSE: This study presents the short- to mid-term implant survival rates, along with the clinical and radiographic outcomes, in a consecutive series of patients who underwent third-generation patellofemoral arthroplasty (PFA) at a non-designer centre. Additionally, it explores the impact of prior surgery on clinical outcomes following PFA. METHODS: A retrospective analysis of prospectively collected data was conducted for 27 PFAs performed in 23 patients between 2016 and 2023 using the Gender Solutions® Patello-Femoral Joint System. Patients had a mean follow-up of 4.3 years, with clinical assessments including the Oxford Knee Score (OKS), Visual Analogue Scale (VAS), Forgotten Joint Score (FJS), and activity levels (TAS, UCLA). Implant survivorship was analysed using Kaplan-Meier estimators, with endpoints of revision and reoperation. RESULTS: The mean age at time of surgery was 51.7 ± 10.5 years, with 92.6% of patients being women. The mean body mass index (BMI) was 28.3 ± 4.5. The 5-year implant survival rate was 100% for revisions and 96.3% for reoperations. Statistically significant improvements were observed in OKS (24.7 ± 8.0 to 39.2 ± 8.3, p < 0.001), VAS (7.1 ± 2.3 to 2.3 ± 2.8, p < 0.001) and range of motion (ROM) (122.1° ± 17° to 134.7° ± 6.8°, p = 0.007). Over 85% of patients achieved good to excellent OKS scores, with 92.3% reporting satisfaction. Patients with prior surgery on the affected knee showed higher satisfaction and greater ROM improvement. Obesity was associated with minor reductions in ROM but did not significantly impact overall outcomes. CONCLUSION: The short- to mid-term results following third-generation PFA demonstrated high survivorship and excellent clinical outcomes in an independent series. Prior surgery and obesity were not associated with poorer clinical outcomes, supporting the consideration of PFA for these patients when appropriately indicated. LEVEL OF EVIDENCE: Level III, retrospective cohort study.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。